Fig. 5
SX-682 alters the immune profile of BrafV600E/Pten−/− melanoma. a mMCPCounter analysis of bulk RNAseq data predicts enrichment for CD8 + T cell infiltrate into tumors following treatment with SX-682 (p < 0.05). b FACS analysis confirms a trend toward increased CD8 + T cells in SX-682 treated BrafV600E/Pten−/− melanoma. c FACS analysis of CD45 + myeloid cells indicated a significant decrease in immunosuppressive CD11b + Ly6G + cells, but no change in total CD11b + cells. d A cytokine array was performed on control and SX-682 treated tumors, identifying a notable decrease in Vegf and an increase in Tnfα. e Cxcl9, Cxcl10, and Pd-l1 expression based upon RNAseq analysis from SX-682 or control treated tumors. All statistical significance determined via Welch’s t-test